The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results.
Elisabeth De Vries
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis (I)
Lowell Anthony
No relevant relationships to disclose
Lucas Sideris
Research Funding - AstraZeneca; Novartis; Roche; Sanofi
Li-Tzong Chen
Consultant or Advisory Role - Novartis (U)
Honoraria - Novartis
Research Funding - Novartis
Jeremie Lebrec
Employment or Leadership Position - Novartis
Zenta Tsuchihashi
Employment or Leadership Position - Novartis
Robert Winkler
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
James Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis
Kjell Oberg
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Other Remuneration - Novartis